U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Bone-marrow foam cells

MedGen UID:
383940
Concept ID:
C1856560
Finding
Synonyms: Bone marrow foam cells; Foam cells (bone marrow); Large vacuolated foam cells ('NP cells') on bone marrow biopsy
 
HPO: HP:0004333

Definition

The presence of foam cells in the bone marrow, generally demonstrated by bone-marrow aspiration or biopsy. Foam cells have a vacuolated appearance due to the presence of complex lipid deposits, giving them a foamy or soap-suds appearance. [from HPO]

Conditions with this feature

Cholesteryl ester storage disease
MedGen UID:
40266
Concept ID:
C0008384
Disease or Syndrome
Deficiency of lysosomal acid lipase causes 2 distinct phenotypes in humans: Wolman disease (WOLD; 620151) and cholesteryl ester storage disease (CESD). WOLD is an early-onset fulminant disorder of infancy with massive infiltration of the liver, spleen, and other organs by macrophages filled with cholesteryl esters and triglycerides. Death occurs early in life. CESD is a milder, later-onset disorder with primary hepatic involvement by macrophages engorged with cholesteryl esters. This slowly progressive visceral disease has a wide spectrum of involvement ranging from early onset with severe cirrhosis to later onset of more slowly progressive hepatic disease with survival into adulthood (summary by Du et al., 2001).
Dysmorphic sialidosis with renal involvement
MedGen UID:
82778
Concept ID:
C0268232
Congenital Abnormality
Niemann-Pick disease, type A
MedGen UID:
78650
Concept ID:
C0268242
Disease or Syndrome
The phenotype of acid sphingomyelinase deficiency (ASMD) occurs along a continuum. Individuals with the severe early-onset form, infantile neurovisceral ASMD, were historically diagnosed with Niemann-Pick disease type A (NPD-A). The later-onset, chronic visceral form of ASMD is also referred to as Niemann-Pick disease type B (NPD-B). A phenotype with intermediate severity is also known as chronic neurovisceral ASMD (NPD-A/B). The most common presenting symptom in NPD-A is hepatosplenomegaly, usually detectable by age three months; over time the liver and spleen become massive in size. Psychomotor development progresses no further than the 12-month level, after which neurologic deterioration is relentless. Failure to thrive typically becomes evident by the second year of life. A classic cherry-red spot of the macula of the retina, which may not be present in the first few months, is eventually present in all affected children. Interstitial lung disease caused by storage of sphingomyelin in pulmonary macrophages results in frequent respiratory infections and often respiratory failure. Most children succumb before the third year of life. NPD-B generally presents later than NPD-A, and the manifestations are less severe. NPD-B is characterized by progressive hepatosplenomegaly, gradual deterioration in liver and pulmonary function, osteopenia, and atherogenic lipid profile. No central nervous system (CNS) manifestations occur. Individuals with NPD-A/B have symptoms that are intermediate between NPD-A and NPD-B. The presentation in individuals with NPD-A/B varies greatly, although all are characterized by the presence of some CNS manifestations. Survival to adulthood can occur in individuals with NPD-B and NPD-A/B.
Niemann-Pick disease, type B
MedGen UID:
78651
Concept ID:
C0268243
Disease or Syndrome
The phenotype of acid sphingomyelinase deficiency (ASMD) occurs along a continuum. Individuals with the severe early-onset form, infantile neurovisceral ASMD, were historically diagnosed with Niemann-Pick disease type A (NPD-A). The later-onset, chronic visceral form of ASMD is also referred to as Niemann-Pick disease type B (NPD-B). A phenotype with intermediate severity is also known as chronic neurovisceral ASMD (NPD-A/B). The most common presenting symptom in NPD-A is hepatosplenomegaly, usually detectable by age three months; over time the liver and spleen become massive in size. Psychomotor development progresses no further than the 12-month level, after which neurologic deterioration is relentless. Failure to thrive typically becomes evident by the second year of life. A classic cherry-red spot of the macula of the retina, which may not be present in the first few months, is eventually present in all affected children. Interstitial lung disease caused by storage of sphingomyelin in pulmonary macrophages results in frequent respiratory infections and often respiratory failure. Most children succumb before the third year of life. NPD-B generally presents later than NPD-A, and the manifestations are less severe. NPD-B is characterized by progressive hepatosplenomegaly, gradual deterioration in liver and pulmonary function, osteopenia, and atherogenic lipid profile. No central nervous system (CNS) manifestations occur. Individuals with NPD-A/B have symptoms that are intermediate between NPD-A and NPD-B. The presentation in individuals with NPD-A/B varies greatly, although all are characterized by the presence of some CNS manifestations. Survival to adulthood can occur in individuals with NPD-B and NPD-A/B.
Niemann-Pick disease, type C2
MedGen UID:
335942
Concept ID:
C1843366
Disease or Syndrome
Niemann-Pick disease type C (NPC) is a slowly progressive lysosomal disorder whose principal manifestations are age dependent. The manifestations in the perinatal period and infancy are predominantly visceral, with hepatosplenomegaly, jaundice, and (in some instances) pulmonary infiltrates. From late infancy onward, the presentation is dominated by neurologic manifestations. The youngest children may present with hypotonia and developmental delay, with the subsequent emergence of ataxia, dysarthria, dysphagia, and, in some individuals, epileptic seizures, dystonia, and gelastic cataplexy. Although cognitive impairment may be subtle at first, it eventually becomes apparent that affected individuals have a progressive dementia. Older teenagers and young adults may present predominantly with apparent early-onset dementia or psychiatric manifestations; however, careful examination usually identifies typical neurologic signs.
Niemann-Pick disease, type C1
MedGen UID:
465922
Concept ID:
C3179455
Disease or Syndrome
Niemann-Pick disease type C (NPC) is a slowly progressive lysosomal disorder whose principal manifestations are age dependent. The manifestations in the perinatal period and infancy are predominantly visceral, with hepatosplenomegaly, jaundice, and (in some instances) pulmonary infiltrates. From late infancy onward, the presentation is dominated by neurologic manifestations. The youngest children may present with hypotonia and developmental delay, with the subsequent emergence of ataxia, dysarthria, dysphagia, and, in some individuals, epileptic seizures, dystonia, and gelastic cataplexy. Although cognitive impairment may be subtle at first, it eventually becomes apparent that affected individuals have a progressive dementia. Older teenagers and young adults may present predominantly with apparent early-onset dementia or psychiatric manifestations; however, careful examination usually identifies typical neurologic signs.
Sialidosis type 2
MedGen UID:
924303
Concept ID:
C4282398
Disease or Syndrome
Sialidosis is an autosomal recessive disorder characterized by the progressive lysosomal storage of sialylated glycopeptides and oligosaccharides caused by a deficiency of the enzyme neuraminidase. Common to the sialidoses is the accumulation and/or excretion of sialic acid (N-acetylneuraminic acid) covalently linked ('bound') to a variety of oligosaccharides and/or glycoproteins (summary by Lowden and O'Brien, 1979). The sialidoses are distinct from the sialurias in which there is storage and excretion of 'free' sialic acid, rather than 'bound' sialic acid; neuraminidase activity in sialuria is normal or elevated. Salla disease (604369) is a form of 'free' sialic acid disease. Classification Lowden and O'Brien (1979) provided a logical nosology of neuraminidase deficiency into sialidosis type I and type II. Type I is the milder form, also known as the 'normosomatic' type or the cherry red spot-myoclonus syndrome. Sialidosis type II is the more severe form with an earlier onset, and is also known as the 'dysmorphic' type. Type II has been subdivided into juvenile and infantile forms. Other terms for sialidosis type II are mucolipidosis I and lipomucopolysaccharidosis.

Recent clinical studies

Etiology

Yuan F, Wei J, Cheng Y, Wang F, Gu M, Li Y, Zhao X, Sun H, Ban R, Zhou J, Xia Z
Inflammation 2024 Apr;47(2):530-542. Epub 2023 Nov 16 doi: 10.1007/s10753-023-01926-y. PMID: 37971565
Huang D, Gao W, Zhong X, Wu H, Zhou Y, Ma Y, Qian J, Ge J
Front Immunol 2023;14:1196704. Epub 2023 May 5 doi: 10.3389/fimmu.2023.1196704. PMID: 37215106Free PMC Article
Robichaud S, Fairman G, Vijithakumar V, Mak E, Cook DP, Pelletier AR, Huard S, Vanderhyden BC, Figeys D, Lavallée-Adam M, Baetz K, Ouimet M
Autophagy 2021 Nov;17(11):3671-3689. Epub 2021 Feb 26 doi: 10.1080/15548627.2021.1886839. PMID: 33590792Free PMC Article
Li JZ, Cao TH, Han JC, Qu H, Jiang SQ, Xie BD, Yan XL, Wu H, Liu XL, Zhang F, Leng XP, Kang K, Jiang SL
Mol Med Rep 2019 Apr;19(4):2660-2670. Epub 2019 Feb 1 doi: 10.3892/mmr.2019.9922. PMID: 30720126Free PMC Article
Stellos K, Gnerlich S, Kraemer B, Lindemann S, Gawaz M
Pharmacol Rep 2008 Jan-Feb;60(1):101-8. PMID: 18276991

Diagnosis

Sugimoto H, Sawa N, Yamagiwa H, Kawada M, Ikuma D, Oba Y, Mizuno H, Sekine A, Yamanouchi M, Hasegawa E, Suwabe T, Nishida A, Kono K, Kinowaki K, Ohashi K, Yamaguchi Y, Ubara Y
Intern Med 2023 Jun 15;62(12):1789-1794. Epub 2022 Oct 26 doi: 10.2169/internalmedicine.0767-22. PMID: 36288989Free PMC Article
Onur İU, Aşula MF, Ekinci C, Mert M
Int Ophthalmol 2019 Jun;39(6):1391-1395. Epub 2018 May 29 doi: 10.1007/s10792-018-0939-6. PMID: 29845436
Karimpoor M, Yebra-Fernandez E, Parhizkar M, Orlu M, Craig D, Khorashad JS, Edirisinghe M
J R Soc Interface 2018 Apr;15(141) doi: 10.1098/rsif.2017.0928. PMID: 29695605Free PMC Article
Milne P, Bigley V, Bacon CM, Néel A, McGovern N, Bomken S, Haniffa M, Diamond EL, Durham BH, Visser J, Hunt D, Gunawardena H, Macheta M, McClain KL, Allen C, Abdel-Wahab O, Collin M
Blood 2017 Jul 13;130(2):167-175. Epub 2017 May 16 doi: 10.1182/blood-2016-12-757823. PMID: 28512190Free PMC Article
Rodrigues AF, Gray RG, Preece MA, Brown R, Hill FG, Baumann U, McKiernan PJ
Arch Dis Child 2006 Oct;91(10):841-4. Epub 2006 May 31 doi: 10.1136/adc.2005.088013. PMID: 16737996Free PMC Article

Therapy

Li JZ, Cao TH, Han JC, Qu H, Jiang SQ, Xie BD, Yan XL, Wu H, Liu XL, Zhang F, Leng XP, Kang K, Jiang SL
Mol Med Rep 2019 Apr;19(4):2660-2670. Epub 2019 Feb 1 doi: 10.3892/mmr.2019.9922. PMID: 30720126Free PMC Article
Teoh GZ, Crowley C, Birchall MA, Seifalian AM
Br J Surg 2015 Jan;102(2):e140-50. doi: 10.1002/bjs.9700. PMID: 25627127
Wang ZX, Wang CQ, Li XY, Feng GK, Zhu HL, Ding Y, Jiang XJ
Mol Cell Biochem 2015 Feb;400(1-2):163-72. Epub 2014 Nov 12 doi: 10.1007/s11010-014-2272-3. PMID: 25389006
Bieghs V, Hendrikx T, van Gorp PJ, Verheyen F, Guichot YD, Walenbergh SM, Jeurissen ML, Gijbels M, Rensen SS, Bast A, Plat J, Kalhan SC, Koek GH, Leitersdorf E, Hofker MH, Lütjohann D, Shiri-Sverdlov R
Gastroenterology 2013 Jan;144(1):167-178.e1. Epub 2012 Oct 3 doi: 10.1053/j.gastro.2012.09.062. PMID: 23041327
Van Eck M, Ye D, Hildebrand RB, Kar Kruijt J, de Haan W, Hoekstra M, Rensen PC, Ehnholm C, Jauhiainen M, Van Berkel TJ
Circ Res 2007 Mar 16;100(5):678-85. Epub 2007 Feb 9 doi: 10.1161/01.RES.0000260202.79927.4f. PMID: 17293475

Prognosis

Guan C, Gan X, Yang C, Yi M, Zhang Y, Liu S
Neurol Sci 2022 Jun;43(6):3957-3966. Epub 2022 Jan 17 doi: 10.1007/s10072-022-05896-1. PMID: 35038048
Karimpoor M, Yebra-Fernandez E, Parhizkar M, Orlu M, Craig D, Khorashad JS, Edirisinghe M
J R Soc Interface 2018 Apr;15(141) doi: 10.1098/rsif.2017.0928. PMID: 29695605Free PMC Article
Oberoi R, Bogalle EP, Matthes LA, Schuett H, Koch AK, Grote K, Schieffer B, Schuett J, Luchtefeld M
PLoS One 2015;10(9):e0137924. Epub 2015 Sep 14 doi: 10.1371/journal.pone.0137924. PMID: 26367277Free PMC Article
Schmohl JU, Daub K, von Ungern-Sternberg SN, Lindemann S, Schönberger T, Geisler T, Gawaz M, Seizer P
Herz 2015 May;40 Suppl 3:269-76. Epub 2013 Dec 5 doi: 10.1007/s00059-013-4012-y. PMID: 24305990
Svennerholm L, Erikson A, Groth CG, Ringdén O, Månsson JE
Dev Neurosci 1991;13(4-5):345-51. doi: 10.1159/000112184. PMID: 1817041

Clinical prediction guides

Ali A, Paladhi A, Hira SK, Singh BN, Pyare R
J Biomed Mater Res B Appl Biomater 2023 May;111(5):1059-1073. Epub 2022 Dec 30 doi: 10.1002/jbm.b.35214. PMID: 36583285
Robichaud S, Fairman G, Vijithakumar V, Mak E, Cook DP, Pelletier AR, Huard S, Vanderhyden BC, Figeys D, Lavallée-Adam M, Baetz K, Ouimet M
Autophagy 2021 Nov;17(11):3671-3689. Epub 2021 Feb 26 doi: 10.1080/15548627.2021.1886839. PMID: 33590792Free PMC Article
Arsiwala T, Pahla J, van Tits LJ, Bisceglie L, Gaul DS, Costantino S, Miranda MX, Nussbaum K, Stivala S, Blyszczuk P, Weber J, Tailleux A, Stein S, Paneni F, Beer JH, Greter M, Becher B, Mostoslavsky R, Eriksson U, Staels B, Auwerx J, Hottiger MO, Lüscher TF, Matter CM
J Mol Cell Cardiol 2020 Feb;139:24-32. Epub 2020 Jan 21 doi: 10.1016/j.yjmcc.2020.01.002. PMID: 31972266
Karimpoor M, Yebra-Fernandez E, Parhizkar M, Orlu M, Craig D, Khorashad JS, Edirisinghe M
J R Soc Interface 2018 Apr;15(141) doi: 10.1098/rsif.2017.0928. PMID: 29695605Free PMC Article
Stellos K, Gnerlich S, Kraemer B, Lindemann S, Gawaz M
Pharmacol Rep 2008 Jan-Feb;60(1):101-8. PMID: 18276991

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...